Vascular side effects associated with the use of BCR::ABL1 inhibitors, particularly with ponatinib and nilotinib [25–28], have emerged as a major concern in the management of CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.